Bharat Book

Biomarker Partnering Terms and Agreements

Press Release   •   Dec 12, 2013 10:51 IST

Dec 12, 2013 : Bharat Book Bureau presents the new report, on 'Biomarker Partnering Terms and Agreements'  provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This report contains over 800 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since January 2007. The chapter is organized by specific diagnpstics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by biomarker partnering company A-Z , stage of development, deal type, therapy area, deal type definitions and biomarker partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.

Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.

Biomarker Partnering Terms and Agreements includes:

Trends in biomarker dealmaking in the biopharma industry since 2007
Analysis of biomarker deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life biomarker deals
Access to several biomarker contract documents
The leading biomarker deals by value since 2007
Most active biomarker dealmakers since 2007
The leading biomarker partnering resources

In Biomarker Partnering Terms and Agreements, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal component type
Specific therapy target

Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Biomarker Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 800 biomarker deals. Analyzing actual contract agreements allows assessment of the following:

Table of contents :

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in biomarker dealmaking

2.1. Introduction
2.2. Biomarker partnering over the years
2.3. Bigpharma biomarker dealmaking activity
2.4. Most active biomarker dealmakers
2.5. Biomarker partnering by deal type
2.6. Biomarker partnering by disease type
2.7. Biomarker partnering by stage of development
2.8 Average deal terms for biomarkers
2.8.1 Biomarker headline values
2.8.2 Biomarker upfront payments
2.8.3 Biomarker milestone payments
2.8.4 Biomarker royalty rates

Chapter 3 – Leading biomarker deals

3.1. Introduction
3.2. Top biomarker deals by value
3.3. Top biomarker deals involving bigpharma

Chapter 4 – Big pharma biomarker deals

4.1. Introduction
4.2. How to use big pharma biomarker partnering deals
4.3. Big pharma biomarker partnering company profiles
Abbott
AstraZeneca
Bayer
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Eisai
Eli Lilly
GlaxoSmithKline
Johnson & Johnson
Kyowa Hakko Kirin
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novartis Molecular Diagnostics
Novo Nordisk
Pfizer
Purdue
Roche
Sanofi
Servier
Takeda
Teva
UCB
 

For more information kindly visit : http://www.bharatbook.com/healthcare-market-research-reports/biomarker-partnering-terms-and-agreements.html

Related link :  http://www.bharatbook.com/market-research-report/pharmaceuticals-and-healthcare.html

About Bharat Book Bureau:

Bharat Book Bureau is the leading market research information provider for market research reports, , company profiles, industry analysis , country reports , business reports, newsletters and online databases Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.

In case the reports don't match your requirement then we can do a specialized Custom Research for you. Our multifarious capabilities, cross-sector expertise and detailed knowledge of various markets, put us in a unique position to take up Custom Research demands of yourself.

Contact us at :

Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Toll Free No for USA/Canada : 1-866-279-8368
Email: info@bharatbook.com 
Website: www.bharatbook.com 
Follow us on twitter: https://twitter.com/researchbook 
Follow us on linked in : http://www.linkedin.com/company/bharat-book-bureau 
Our Blog : http://blog.bharatbook.com/ 


Bharat Book Bureau, the leading market research information aggregator provides market research reports, company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.